Evidence-Based Practice: Temozolomide Beyond Glioblastoma

Area of Science:

• Neuro-oncology
• Chemotherapy research
• Clinical trial analysis

Background:

• Temozolomide is a standard first-line chemotherapy for newly diagnosed glioblastoma.
• Its efficacy and safety profile warrant investigation in diverse glioma contexts.

Purpose of the Study:

• To review the application of temozolomide in various glioma types beyond initial glioblastoma treatment.
• To assess its role in recurrent glioblastoma, elderly patients, diffuse gliomas, and other rare tumors.

Main Methods:

• Systematic literature review of clinical studies and trials.
• Analysis of survival data, toxicity profiles, and treatment outcomes.
• Evaluation of temozolomide efficacy across different glioma histologies and patient populations.

Main Results:

• Temozolomide demonstrated improved survival in elderly glioblastoma and anaplastic gliomas.
• It showed comparable efficacy and lower toxicity than standard treatments in specific low-grade and pediatric high-grade gliomas.
• Benefits extended to non-glioblastoma brain tumors, indicating broader utility.

Conclusions:

• Temozolomide offers significant survival benefits and manageable toxicity in a wider range of gliomas.
• Further research into predictive biomarkers and combination therapies is crucial for optimizing temozolomide's role in neuro-oncology.